{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:22:28Z","timestamp":1784931748853,"version":"3.55.0"},"reference-count":73,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Low-molecular-weight heparins are a class of drugs derived from the enzymatic depolymerization of unfractionated heparin that includes enoxaparin. Several studies have been performed on enoxaparin in recent years, in particular for the prevention and treatment of venous thromboembolism and for the treatment of acute coronary syndrome. Furthermore, the use of enoxaparin has been extended to other clinical situations that require antithrombotic pharmacological prevention, such as hemodialysis and recurrent abortion. In this review, we report the main clinical experiences of using enoxaparin in the prevention of VTE in nonsurgical patients.<\/jats:p>","DOI":"10.3390\/medicina60010156","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T04:03:26Z","timestamp":1705291406000},"page":"156","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Update on the Pharmacological Actions of Enoxaparin in Nonsurgical Patients"],"prefix":"10.3390","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2656-5467","authenticated-orcid":false,"given":"Egidio","family":"Imbalzano","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana","family":"Orlando","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6681-0183","authenticated-orcid":false,"given":"Giuseppe","family":"Dattilo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Gigliotti De Fazio","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0881-5429","authenticated-orcid":false,"given":"Giuseppe","family":"Camporese","sequence":"additional","affiliation":[{"name":"General Medicine Department, Thrombotic and Haemorrhagic Disorders Unit, Department of Internal Medicine, University Hospital of Padua, 35131 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9227-0360","authenticated-orcid":false,"given":"Vincenzo","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Translational Science, University Vanvitelly, 81025 Caserta, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Perrella","sequence":"additional","affiliation":[{"name":"Unit Emerging Infectious Disease, Ospedali dei Colli, P.O. D. Cotugno, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Futura","family":"Bernardi","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Universit\u00e0 degli Studi della Campania Luigi Vanvitelli, 80100 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8484-4598","authenticated-orcid":false,"given":"Pierpaolo","family":"Di Micco","sequence":"additional","affiliation":[{"name":"AFO Medicina, P.O. Santa Maria delle Grazie, ASL Napoli 2 Nord, 80078 Pozzuoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1161\/01.CIR.98.15.1575","article-title":"Low-molecular-weight heparin: A review of the results of recent studies of the treatment of venous thromboembolism and unstable angina","volume":"98","author":"Hirsh","year":"1998","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/pharmrev.122.000684","article-title":"Pharmacology of Heparin and Related Drugs: An Update","volume":"75","author":"Hogwood","year":"2023","journal-title":"Pharmacol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1517\/14656566.2011.570261","article-title":"Enoxaparin: A pharmacologic and clinical review","volume":"12","author":"Iqbal","year":"2011","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2165\/00003088-200342120-00003","article-title":"Pharmacodynamic and pharmacokinetic properties of enoxaparin: Implications for clinical practice","volume":"42","author":"Fareed","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00129784-200101060-00010","article-title":"Enoxaparin: In the prevention of venous thromboembolism in medical patients","volume":"1","author":"Warner","year":"2001","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"48M","DOI":"10.1016\/S0002-9149(00)01481-8","article-title":"Thrombosis prophylaxis in the acutely ill medical patient: Insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial","volume":"86","author":"Turpie","year":"2000","journal-title":"Am. J. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1155\/2002\/310841","article-title":"Economic evaluation of the MEDENOX trial: A Canadian perspective. Medical Patients with Enoxaparin","volume":"9","author":"Lamy","year":"2002","journal-title":"Can. Respir. J."},{"key":"ref_8","first-page":"21","article-title":"Efficacy and safety of enoxaparin during hemodialysis: Results from the HENOX study","volume":"94","author":"Vareesangthip","year":"2011","journal-title":"J. Med. Assoc. Thai."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/ckj\/sfaa057","article-title":"Efficacy of enoxaparin in preventing coagulation during high-flux haemodialysis, expanded haemodialysis and haemodiafiltration","volume":"14","author":"Santos","year":"2020","journal-title":"Clin. Kidney J."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Wiegele, M., Adelmann, D., Dibiasi, C., Pausch, A., Baierl, A., and Schaden, E. (2021). Monitoring of Enoxaparin during Hemodialysis Covered by Regional Citrate Anticoagulation in Acute Kidney Injury: A Prospective Cohort Study. J. Clin. Med., 10.","DOI":"10.3390\/jcm10194491"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1586\/14779072.5.3.387","article-title":"Enoxaparin in acute coronary syndromes","volume":"5","author":"Lee","year":"2007","journal-title":"Expert. Rev. Cardiovasc. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e914","DOI":"10.1161\/CIR.0000000000000769","article-title":"Call to Action to Prevent Venous Thromboembolism in Hospitalized Patients: A Policy Statement From the American Heart Association","volume":"141","author":"Henke","year":"2020","journal-title":"Circulation"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","article-title":"Epidemiology of venous thromboembolism","volume":"12","author":"Heit","year":"2015","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e2240373","DOI":"10.1001\/jamanetworkopen.2022.40373","article-title":"Trends and Risk Factors for Venous Thromboembolism Among Hospitalized Medical Patients","volume":"5","author":"Neeman","year":"2022","journal-title":"JAMA Netw. Open."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.3346\/jkms.2016.31.11.1828","article-title":"Pharmacological and Mechanical Thromboprophylaxis in Critically Ill Patients: A Network Meta-Analysis of 12 Trials","volume":"31","author":"Park","year":"2016","journal-title":"J. Korean Med. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/SLA.0000000000005709","article-title":"Systematic Review and Meta-analysis of the Additional Benefit of Pharmacological Thromboprophylaxis for Endovenous Varicose Vein Interventions","volume":"278","author":"Turner","year":"2023","journal-title":"Ann. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1182\/bloodadvances.2018022954","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: Prophylaxis for hospitalized and nonhospitalized medical patients","volume":"2","author":"Cushman","year":"2018","journal-title":"Blood Adv."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1378\/chest.1412S3","article-title":"Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Guyatt","year":"2012","journal-title":"Chest"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1067\/mhj.2003.189","article-title":"Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease","volume":"145","author":"Kleber","year":"2003","journal-title":"Am. Heart J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1056\/NEJMoa1111288","article-title":"Low-molecular-weight heparin and mortality in acutely ill medical patients","volume":"365","author":"Kakkar","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11239-006-7732-5","article-title":"Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: Methodology for the EXCLAIM study","volume":"22","author":"Hull","year":"2006","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Lee, A.Y., Bauersachs, R., Janas, M.S., Jarner, M.F., Kamphuisen, P.W., Meyer, G., Khorana, A.A., and CATCH Investigators (2013). CATCH: A randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-284"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S1474-4422(13)70101-7","article-title":"Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in patients receiving anti-thrombotic treatment","volume":"12","author":"Diener","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.eururo.2016.03.017","article-title":"The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-na\u00efve Metastatic Castration-resistant Prostate Cancer","volume":"70","author":"Evans","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.100.15.1593","article-title":"Enoxaparin prevents death and cardiac ischemic events in unstable angina\/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2147\/vhrm.2007.3.2.221","article-title":"Enoxaparin injection for the treatment of high-risk patients with non-ST elevation acute coronary syndrome","volume":"3","author":"Schultheiss","year":"2007","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators (2001). Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction. Lancet, 358, 605\u2013613.","DOI":"10.1016\/S0140-6736(01)05775-0"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0828-282X(10)70441-4","article-title":"Safety and effectiveness of enoxaparin following fibrinolytic therapy: Results of the Acute Myocardial Infarction (AMI)-QUEBEC registry","volume":"26","author":"Schampaert","year":"2010","journal-title":"Can. J. Cardiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/14779072.5.5.851","article-title":"ExTRACT-TIMI 25 trial: Clarifying the role of enoxaparin in patients with ST-elevation myocardial infarction receiving fibrinolysis","volume":"5","author":"Gabriel","year":"2007","journal-title":"Expert. Rev. Cardiovasc. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1056\/NEJMoa052711","article-title":"Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention","volume":"355","author":"Montalescot","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1023\/A:1008803203290","article-title":"The Essence Trial: Efficacy and Safety of Subcutaneous Enoxaparin in Unstable Angina and Non-Q-Wave MI: A Double-Blind, Randomized, Parallel-Group, Multicenter Study Comparing Enoxaparin and Intravenous Unfractionated Heparin: Methods and Design","volume":"4","author":"Cohen","year":"1997","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"SYNERGY Executive Committee (2002). Superior Yield of the New strategy of Enoxaparin, Revascularization and GlYcoprotein IIb\/IIIa inhibitors. The SYNERGY trial: Study design and rationale. Am. Heart J., 143, 952\u2013960.","DOI":"10.1067\/mhj.2002.122120"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2005-02-0626","article-title":"Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: A systematic review of safety and efficacy","volume":"106","author":"Greer","year":"2005","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"American College of Obstetricians and Gynecologists\u2019 Committee on Practice Bulletins\u2014Obstetrics (2018). ACOG Practice Bulletin No. 196: Thromboembolism in Pregnancy. Obstet. Gynecol., 132, e1\u2013e17.","DOI":"10.1097\/AOG.0000000000002706"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"102070","DOI":"10.1016\/j.jogoh.2021.102070","article-title":"Therapeutic role of enoxaparin in intra-uterine growth restriction: A randomized clinical trial","volume":"50","author":"Shirazi","year":"2021","journal-title":"J. Gynecol. Obstet. Hum. Reprod."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1055\/s-0032-1302449","article-title":"Inferior vena cava filters for primary prophylaxis: When are they indicated?","volume":"29","author":"Stavropoulos","year":"2012","journal-title":"Semin. Intervent Radiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jvir.2010.09.032","article-title":"Modeling blood flow in a tilted inferior vena cava filter: Does tilt adversely affect hemodynamics?","volume":"22","author":"Singer","year":"2011","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2013.343","article-title":"Indications, complications, and management of inferior vena cava filters: The experience in 952 patients at an academic hospital with a level I trauma center","volume":"173","author":"Sarosiek","year":"2013","journal-title":"JAMA Intern. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.2017.1928","article-title":"Antithrombotic Therapy for Venous Thromboembolic Disease","volume":"317","author":"Jain","year":"2017","journal-title":"JAMA"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJM200103013440902","article-title":"Clivarin: Assessment of Regression of Thrombosis, Efficacy, and Safety. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis","volume":"344","author":"Breddin","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1055\/s-0039-1677796","article-title":"Low-Molecular-Weight Heparin in Cancer Patients: Overview and Indications","volume":"39","author":"Voigtlaender","year":"2019","journal-title":"Hamostaseologie"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/jama.2015.3780","article-title":"Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: A randomized clinical trial","volume":"313","author":"Mismetti","year":"2015","journal-title":"JAMA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41575-021-00492-8","article-title":"International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease","volume":"18","author":"Olivera","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jceh.2021.11.003","article-title":"Portal Vein Thrombosis in Cirrhosis","volume":"12","author":"Shukla","year":"2022","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12959-021-00345-z","article-title":"Patients with venous thromboembolism after spontaneous intracerebral hemorrhage: A review","volume":"19","author":"Cai","year":"2021","journal-title":"Thromb. J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/ene.13830","article-title":"Early thrombosis prophylaxis with enoxaparin is not associated with hematoma expansion in patients with spontaneous intracerebral hemorrhage","volume":"26","author":"Ianosi","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2147\/JBM.S248988","article-title":"In vitro Fertilization Procedures with Embryo Transfer and Their Association with Thrombophilia, Thrombosis and Early Antithrombotic Treatments","volume":"11","author":"Russo","year":"2020","journal-title":"J. Blood Med."},{"key":"ref_51","unstructured":"Prophylaxis and Treatment of VTE in Renal Impairment (2023, October 16). Approved September 2020 and Reviewed in September 2023 by Drugs and Therapeutics Committee. Available online: gloshospitals.nhs.uk."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1161\/CIRCULATIONAHA.111.084996","article-title":"Antithrombotic therapy in patients with chronic kidney disease","volume":"125","author":"Capodanno","year":"2012","journal-title":"Circulation"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1177\/0018578720954151","article-title":"Evaluation of Enoxaparin for Inpatient Venous Thromboembolism Prophylaxis in End-Stage Renal Disease Patients on Hemodialysis","volume":"56","author":"Sacks","year":"2021","journal-title":"Hosp. Pharm."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1096\/fj.07-8450com","article-title":"P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins","volume":"21","author":"Hostettler","year":"2007","journal-title":"FASEB J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e2854","DOI":"10.1002\/jmr.2854","article-title":"Quantification of heparin\u2019s antimetastatic effect by single-cell force spectroscopy","volume":"34","author":"Liebsch","year":"2021","journal-title":"J. Mol. Recognit."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1160\/TH09-01-0059","article-title":"Antimigratory and antimetastatic effect of heparin-derived 4-18 unit oligosaccharides in a preclinical human melanoma metastasis model","volume":"102","author":"Kenessey","year":"2009","journal-title":"Thromb. Haemost."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/JBM.S285214","article-title":"Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The FONDENOXAVID Study","volume":"12","author":"Cardillo","year":"2021","journal-title":"J. Blood Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"569567","DOI":"10.3389\/fmed.2020.569567","article-title":"Thromboprofilaxys With Fondaparinux vs. Enoxaparin in Hospitalized COVID-19 Patients: A Multicenter Italian Observational Study","volume":"7","author":"Russo","year":"2020","journal-title":"Front. Med."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Di Micco, P., Tufano, A., Cardillo, G., Imbalzano, E., Amitrano, M., Lodigiani, C., Bellizzi, A., Camporese, G., Cavalli, A., and De Stefano, C. (2021). The Impact of Risk-Adjusted Heparin Regimens on the Outcome of Patients with COVID-19 Infection. A Prospective Cohort Study. Viruses, 13.","DOI":"10.3390\/v13091720"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Di Micco, P., Imbalzano, E., Russo, V., Attena, E., Mandaliti, V., Orlando, L., Lombardi, M., Di Micco, G., Camporese, G., and Annunziata, S. (2021). Heparin and SARS-CoV-2: Multiple Pathophysiological Links. Viruses, 13.","DOI":"10.3390\/v13122486"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1182\/bloodadvances.2019000975","article-title":"American Society of Hematology 2019 guidelines for management of venous thromboembolism: Prevention of venous thromboembolism in surgical hospitalized patients","volume":"3","author":"Anderson","year":"2019","journal-title":"Blood Adv."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa012385","article-title":"Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer","volume":"346","author":"Bergqvist","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3109\/00365529309098302","article-title":"Safety of enoxaparin and dextran-70 in the prevention of venous thromboembolism in digestive surgery. A play-the-winner-designed study","volume":"28","author":"Reiertsen","year":"1993","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"336","DOI":"10.2106\/00004623-200103000-00004","article-title":"Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group","volume":"83","author":"Comp","year":"2001","journal-title":"J. Bone Joint Surg. Am."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1056\/NEJM199609053351002","article-title":"Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement","volume":"335","author":"Bergqvist","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomised trial","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1111\/j.1538-7836.2007.02764.x","article-title":"The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement","volume":"5","author":"Lassen","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1056\/NEJMoa0810773","article-title":"Apixaban or enoxaparin for thromboprophylaxis after knee replacement","volume":"361","author":"Lassen","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_71","first-page":"2339","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: A meta-analysis of randomized controlled trials","volume":"125","author":"Li","year":"2012","journal-title":"Chin. Med. J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after hip replacement","volume":"363","author":"Lassen","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): A randomised double-blind trial","volume":"375","author":"Lassen","year":"2010","journal-title":"Lancet"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/1\/156\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:46:52Z","timestamp":1760104012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/1\/156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,15]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["medicina60010156"],"URL":"https:\/\/doi.org\/10.3390\/medicina60010156","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,15]]}}}